Photodynamic therapy of tumors can lead to development of systemic antigen-specific immune response

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Mroz, Pawel ^a,b   Szokalska, Angelika ^a,c   Wu, Mei X ^a,b,d   Hamblin, Michael R ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; ANTIGEN; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL ISOLATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOLYSIS; EPITOPE MAPPING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR IMMUNITY; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; COLON TUMOR; CYTOLOGY; DIMERIZATION; DISEASE MODEL; FLOW CYTOMETRY; IMMUNE SYSTEM; IMMUNOLOGY; METABOLISM; METHODOLOGY; PHOTOCHEMOTHERAPY; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIGENS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIMERIZATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNE SYSTEM; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650770665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015194     Document Type: Article

References (65)

1. van der Bruggen P, Van den Eynde BJ (2006) Processing and presentation of tumor antigens and vaccination strategies. Curr Opin Immunol 18: 98-104.
2. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9: 684-693.
3. Hirohashi Y, Torigoe T, Inoda S, Kobayasi J, Nakatsugawa M, et al. (2009) The functioning antigens: beyond just as the immunological targets. Cancer Sci 100: 798-806.
4. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173: 1373-1384.
5. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, et al. (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182: 689-698.
6. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
7. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, et al. (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179: 921-930.
8. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, et al. (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLAA1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176: 1453-1457.
9. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, et al. (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180: 35-42.
10. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, et al. (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489-495.
11. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, et al. (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanomaderived tumor-infiltrating lymphocytes. J Exp Med 179: 1005-1009.
12. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, et al. (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A 92: 7976-7980.
13. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, et al. (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 369: 67-71.
14. Monach PA, Meredith SC, Siegel CT, Schreiber H (1995) A unique tumor antigen produced by a single amino acid substitution. Immunity 2: 45-59.
15. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, et al. (1996) A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183: 1185-1192.
16. Dubey P, Hendrickson RC, Meredith SC, Siegel CT, Shabanowitz J, et al. (1997) The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 185: 695-705.
17. Laheru D, Jaffee EM (2005) Immunotherapy for pancreatic cancer-science driving clinical progress. Nat Rev Cancer 5: 459-467.
18. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, et al. (2005) Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocytemacrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23: 720-731.
19. Mroz P, Tegos GP, Gali H, Wharton T, Sarna T, et al. (2007) Photodynamic therapy with fullerenes. Photochem Photobiol Sci 6: 1139-1149.
20. Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and antitumour immunity. Nat Rev Cancer 6: 535-545.
21. Jalili A, Makowski M, Switaj T, Nowis D, Wilczynski GM, et al. (2004) Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 10: 4498-4508.
22. Dougherty TJ (2002) An update on photodynamic therapy applications. J Clin Laser Med Surg 20: 3-7.
23. Huang Z (2005) A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat 4: 283-293.
24. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, et al. (1998) Photodynamic therapy. J Natl Cancer Inst 90: 889-905.
25. Korbelik M (1996) Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 14: 329-334.
26. Korbelik M, Sun J, Cecic I (2005) Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 65: 1018-1026.
27. Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, et al. (2003) Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 88: 1772-1779.
28. Cecic I, Stott B, Korbelik M (2006) Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy. Int Immunopharmacol 6: 1259-1266.
29. Korbelik M, Cecic I, Merchant S, Sun J (2008) Acute phase response induction by cancer treatment with photodynamic therapy. Int J Cancer 122: 1411-1417.
30. Cecic I, Korbelik M (2002) Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett 183: 43-51.
31. Korbelik M (2006) PDT-associated host response and its role in the therapy outcome. Lasers Surg Med 38: 500-508.
32. Krosl G, Korbelik M, Dougherty GJ (1995) Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br J Cancer 71: 549-555.
33. Korbelik M, Cecic I (2008) Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy. J Photochem Photobiol B 93: 53-59.
34. Cecic I, Serrano K, Gyongyossy-Issa M, Korbelik M (2005) Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy. Cancer Lett 225: 215-223.
35. Cecic I, Korbelik M (2006) Deposition of complement proteins on cells treated by photodynamic therapy in vitro. J Environ Pathol Toxicol Oncol 25: 189-203.
36. Cecic I, Sun J, Korbelik M (2006) Role of complement anaphylatoxin C3a in photodynamic therapy-elicited engagement of host neutrophils and other immune cells. Photochem Photobiol 82: 558-562.
37. Stott B, Korbelik M (2007) Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy. Cancer Immunol Immunother 56: 649-658.
38. Gollnick SO, Owczarczak B, Maier P (2006) Photodynamic therapy and antitumor immunity. Lasers Surg Med 38: 509-515.
39. Cecic I, Parkins CS, Korbelik M (2001) Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors. Photochem Photobiol 74: 712-720.
40. Dal Porto J, Johansen TE, Catipovic B, Parfiit DJ, Tuveson D, et al. (1993) A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A 90: 6671-6675.
41. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78.
42. Parkinson-Lawrence EJ, Dean CJ, Chang M, Hopwood JJ, Meikle PJ, et al. (2005) Immunochemical analysis of CD107a (LAMP-1). Cell Immunol 236: 161-166.
43. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, et al. (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20: 2624-2632.
44. Quesnel B (2008) Tumor dormancy and immunoescape. APMIS 116: 685-694.
45. Stewart TJ, Abrams SI (2008) How tumours escape mass destruction. Oncogene 27: 5894-5903.
46. Garrido F, Algarra I., Garcia-Lora AM The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible ''hard'' lesions. Cancer Immunol Immunother 59: 1601-1606.
47. Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, et al. (2002) Assumptions of the tumor 'escape' hypothesis. Semin Cancer Biol 12: 81-86.
48. Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, et al. (1997) Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15: 387-394.
49. Kabingu E, Oseroff AR, Wilding GE, Gollnick SO (2009) Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy. Clin Cancer Res 15: 4460-4466.
50. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, et al. (1996) Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol 156: 224-231.
51. Wang M, Chen PW, Bronte V, Rosenberg SA, Restifo NP (1995) Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother Emphasis Tumor Immunol 18: 139-146.
52. Irvine KR, Rao JB, Rosenberg SA, Restifo NP (1996) Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156: 238-245.
53. Paglia P, Chiodoni C, Rodolfo M, Colombo MP (1996) Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183: 317-322.
54. Korbelik M, Cooper PD (2007) Potentiation of photodynamic therapy of cancer by complement: the effect of gamma-inulin. Br J Cancer 96: 67-72.
55. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, et al. (1996) The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 93: 9730-9735.
56. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32: 3267-3275.
57. Beatty GL, Paterson Y (2000) IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 165: 5502-5508.
58. Takeda J, Sato Y, Kiyosawa H, Mori T, Yokoya S, et al. (2000) Anti-tumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding beta-galactosidase fused to an envelope protein of endogenous retrovirus. Cell Immunol 204: 11-18.
59. McWilliams JA, Sullivan RT, Jordan KR, McMahan RH, Kemmler CB, et al. (2008) Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine 26: 1863-1873.
60. Castano AP, Mroz P, Wu MX, Hamblin MR (2008) Photodynamic therapy plus low-dose cyclophosphamide generates antitumor immunity in a mouse model. Proc Natl Acad Sci U S A 105: 5495-5500.
61. Mule JJ, Custer MC, Travis WD, Rosenberg SA (1992) Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 148: 2622-2629.
62. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, et al. (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1706.
63. Lethe B, van den Eynde B, van Pel A, Corradin G, Boon T (1992) Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 22: 2283-2288.
64. Hance KW, Rogers CJ, Zaharoff DA, Canter D, Schlom J, et al. (2009) The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines. Clin Cancer Res 15: 2387-2396.
65. Donohue KB, Grant JM, Tewalt EF, Palmer DC, Theoret MR, et al. (2006) Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 119: 63-73.